

About Saliva Testing



The Science of Saliva Testing

Estrogens (estrone, estradiol and estriol), progesterone, testosterone, DHEA-S and cortisol are routinely measured in saliva at ZRT. Why saliva? Steroid hormones in the bloodstream are mostly (95-99%) bound to carrier proteins (hormone-binding globulins, albumin), and in this form they are unavailable to target tissues. Only the unbound fraction freely diffuses into tissues, including the salivary gland. Hormone levels in saliva therefore represent the quantity of the hormone that is currently available to target tissues and actively exerting specific effects on the body. Because of this, salivary hormone levels often relate to specific symptoms of hormone excesses or deficiencies. Research at ZRT has demonstrated clear correlations between salivary hormone levels and reported symptoms. The rationale for and clinical utility of saliva testing is well documented¹⁻¹³.

The very small concentrations of salivary hormones (only 1 – 5% of the total hormone levels that include protein-bound hormone found in serum) necessitate extremely sensitive assay methods. This is a particular issue for estrogens, which are present in very minute quantities in saliva, especially in older populations such as postmenopausal women. ZRT is unique as the only commercial laboratory using extracted saliva testing for estrogens. Extraction removes contaminants that interfere with the assay and concentrates the sample, significantly improving assay sensitivity compared to the “direct” assay methods available commercially¹⁴. In fact, poor correlations between serum tests and non-extraction salivary estradiol assays have unfortunately led to some skepticism about saliva testing. Also, because of the extremely sensitive assays, it is important to avoid blood contamination of saliva as a result of oral injury, therefore toothbrushing must be avoided before collecting saliva for testing¹⁵. Saliva testing may also not be appropriate for sublingual hormone users unless samples are obtained at least 36 hours after the last dose. Blood spot testing is a preferred option for these patients.

Conversely, when some hormones, notably progesterone, are administered topically, saliva levels can rise higher than serum levels^{16,17}. This is because progesterone is carried on the surface of red blood cells to target tissues including the salivary glands, where there is rapid uptake and release of the hormone into tissues and saliva, leaving very little hormone in the venous blood returning from the tissues¹⁸. Tissue levels of progesterone have been found to be very high after topical progesterone use¹⁹⁻²¹, and a biological response can be demonstrated, e.g., the reduction of endometrial cell proliferation caused by estrogen therapy²². Serum testing for progesterone therefore grossly underestimates the amount of progesterone that is being delivered to tissues when progesterone is applied topically to the skin.

DHEA-S, the sulfated storage form of DHEA, is measured rather than DHEA because its levels are more stable (DHEA has a much shorter half life in blood) and at ZRT it has been found to correlate very well with reported clinical symptoms. However, as a conjugated hormone that does not diffuse into saliva as rapidly as the unconjugated hormones

measured in ZRT’s other hormone assays, its passage into saliva is flow rate dependent¹² and therefore flow stimulants such as gum chewing are not advised prior to saliva collection.

Research at ZRT shows good correlations between salivary hormone levels and dosages of hormones given exogenously. Saliva testing is therefore a good option for monitoring hormone therapy and adjusting dosages if necessary.

Advantages

- Saliva testing, unlike serum tests, measures the bioavailable (“free”) levels of steroid hormones, correlating with symptomatology and potential deficiency
- Samples are collected by the patient at home, allowing convenient timing of collection especially for cortisol, which must be measured at specific times of the day or night
- Convenience of collection allows frequent sampling, e.g., during a menstrual cycle to determine fertility problems
- Hormone levels can be assessed during topical hormone supplementation
- Saliva collection avoids the stress of a blood draw, which can affect levels of cortisol
- Hormones are stable in saliva at room temperature for up to 2 weeks, allowing for worldwide shipment and convenient mailing of samples for testing
- Saliva testing is less expensive than conventional serum testing

Clinical Utility

Saliva Testing can help providers:

- Identify hormone imbalances prior to the appearance of symptoms or disease
- Identify specific hormone imbalances associated with symptoms
- Establish hormone baselines prior to surgery or beginning therapy
- Monitor hormone levels while supplementing, allowing for individualized hormone dosing
- Track patient symptoms and hormone levels using ZRT’s comparative history reports provided with follow-up testing

Customer Support

- ZRT’s Hormone Evaluation report includes hormone test results, details of hormone supplements and current symptoms reported by the patient, and ZRT analysis
- The report is returned to the patient or ordering healthcare provider in 5 – 7 business days and is also available via secure internet access
- ZRT staff physicians are available for enquiries without appointment, 8:00 a.m. to 5:00 p.m. weekdays

REFERENCES

1. Cardoso EM, Arregger AL, Tumilasci OR, Contreras LN. Diagnostic value of salivary cortisol in Cushing's syndrome (CS). *Clin Endocrinol (Oxf)*. 2009;70(4):516-21.
2. Gröschl M. Current status of salivary hormone analysis. *Clin Chem*. 2008;54(11):1759-69.
3. Arregger AL, Contreras LN, Tumilasci OR, Aquilano DR, Cardoso EM. Salivary testosterone: a reliable approach to the diagnosis of male hypogonadism. *Clin Endocrinol (Oxf)*. 2007;67(5):656-62.
4. Gozansky WS, Lynn JS, Laudenslager ML, Kohrt WM. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic-pituitary-adrenal axis activity. *Clin Endocrinol (Oxf)* 2005;63(3):336-41.
5. Zava D. Saliva hormone testing. *Townsend Letter for Doctors & Patients* 2004;January:120-4.
6. Stephenson K. The salivary hormone profile in the clinical evaluation of women. *Int J Pharmaceutical Compounding* 2004;8(6):427-435.
7. Ishikawa M, Sengoku K, Tamate K, Takaoka Y, Kane M, Fottrell PF. The clinical usefulness of salivary progesterone measurement for the evaluation of the corpus luteum function. *Gynecol Obstet Invest* 2002;53(1):32-7.
8. Gann PH, Giovanazzi S, Van Horn L, Branning A, Chatterton RT Jr. Saliva as a medium for investigating intra- and interindividual differences in sex hormone levels in premenopausal women. *Cancer Epidemiol Biomarkers Prev* 2001;10(1):59-64.
9. Hofman LF. Human saliva as a diagnostic specimen. *J Nutr* 2001;131(5):1621S-5S.
10. Bolaji II, Tallon DF, O'Dwyer E, Fottrell PF. Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzyme immunoassay. *Gynecol Endocrinol*. 1993;7(2):101-10.
11. Worthman CM, Stallings JF, Hofman LF. Sensitive salivary estradiol assay for monitoring ovarian function. *Clin Chem*. 1990;36(10):1769-73.
12. Vining RF, McGinley RA. Hormones in saliva. *CRC Crit Rev Clin Lab Sci* 1986;23(2):95-146.
13. Riad-Fahmy D, Read GF, Walker RF. Salivary steroid assays for assessing variation in endocrine activity. *J Steroid Biochem* 1983;19:265-272.
14. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. *Steroids*. 2003;68(14):1173-8.
15. Kivlighan KT, Granger DA, Schwartz EB, Nelson V, Curran M, Shirtcliff EA. Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. *Horm Behav* 2004;46(1):39-46.
16. O'Leary P, Feddema P, Chan K, Taranto M, Smith M, Evans S. Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women. *Clin Endocrinol (Oxf)* 2000;53(5):615-20.
17. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. *Am J Obstet Gynecol*. 1999;180(6 pt 1):1504-1511.
18. Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. *Menopause*. 2005;12(2):232-7.
19. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. *Fertil Steril* 1995;63:785-91.
20. De Boever J, Verheugen C, Van Maele G, Vandekerckhove D. Steroid concentrations in serum, glandular breast tissue, and breast cyst fluid of control and progesterone-treated patients. In: *Endocrinology of Cystic Breast Disease*, Ed. A. Angeli, Raven Press, New York, 1983 pp. 93-99.
21. Waddell BJ, O'Leary PC. Distribution and metabolism of topically applied progesterone in a rat model. *J Steroid Biochem Mol Biol* 2002;80:449-455.
22. Leonetti HB, Landes J, Steinberg D, Anasti JN. Topical progesterone cream as an alternative progestin in hormone therapy. *Altern Ther Health Med* 2005;11(6):36-38.